|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
1983-1-19
|
|
pubmed:abstractText |
Buspirone, an effective antianxiety compound, produced a dose-dependent, relatively prolonged increase in rat plasma prolactin (PRL) levels. The stimulation of PRL secretion by buspirone was additive with the effect of alpha-methyl-p-tyrosine (AMPT) or gamma-butyrolactone. In vitro, buspirone itself had no effect on the release of PRL from rat pituitary glands but it blocked the inhibitory action of dopamine (DA). Buspirone also increased DA turnover in the striatum as measured by the AMPT-induced depletion of striatal DA levels. These results demonstrate the ability of buspirone to block pituitary and striatal DA receptors.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0033-3158
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
78
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
49-53
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:6128756-Animals,
pubmed-meshheading:6128756-Anti-Anxiety Agents,
pubmed-meshheading:6128756-Buspirone,
pubmed-meshheading:6128756-Corpus Striatum,
pubmed-meshheading:6128756-Dopamine,
pubmed-meshheading:6128756-Dose-Response Relationship, Drug,
pubmed-meshheading:6128756-Male,
pubmed-meshheading:6128756-Pituitary Gland, Anterior,
pubmed-meshheading:6128756-Prolactin,
pubmed-meshheading:6128756-Pyrimidines,
pubmed-meshheading:6128756-Rats,
pubmed-meshheading:6128756-Rats, Inbred Strains,
pubmed-meshheading:6128756-Receptors, Dopamine,
pubmed-meshheading:6128756-Synaptic Transmission
|
|
pubmed:year |
1982
|
|
pubmed:articleTitle |
Effect of buspirone on rat plasma prolactin levels and striatal dopamine turnover.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
